Delivery Order SPE2DB20D9127-SPE2DB22FD4BW
- Not listed
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $26,654.84, is for the delivery of KADCYLA 160 MG vials. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which runs through December 31, 2025. The IDC...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $39,982.26 contract, awarded on April 18, 2024, is for the delivery of KADCYLA 160 MG vials by May 9, 2024. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued up to $499,999,999, which allows the DLA to issue orders for a...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $49,247.04 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 160 mg vials of the drug Kadcyla, with a completion date of January 17, 2025. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued at $499,999,999, which allows the DLA to issue firm fixed-price orders...
- The Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $15,358.74 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Kadcyla 100 mg vials, and has an ultimate completion date of July 2, 2024. This delivery order is part of a larger single-award Indefinite Delivery Contract (IDC) valued at up to $499,999,999, which DMS Pharmaceutical Group holds with the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of KADCYLA 100 MG VIALS and has an ultimate completion date of August 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of pharmaceutical products and medical supplies to the Department of Defense...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the delivery of 100 mg vials of the oncology drug Kadcyla. The contract has a completion date of July 5, 2024 and uses a Firm Fixed Price pricing structure. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $18,526.83 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. Through this IDC, DMS Pharmaceutical Group provides a comprehensive range of...
- This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $33,942.56 firm fixed-price delivery order is for the supply of KADCYLA 160 MG vials, with a completion date of July 25, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
- The U.S. government's Defense Logistics Agency (DLA) awarded a Delivery Order contract, valued at $80,285.70, to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. This Delivery Order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, valued up to $499,999,999, which provides a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. The contract...
- The U.S. government agency, the Defense Logistics Agency (DLA), has awarded a firm fixed-price delivery order contract worth $10,831.55 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of various pharmaceutical products and medical supplies, including rehydration salts, to support the recurring medical needs of military health facilities worldwide. This delivery order contract is part of a...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB22FD4BWDelivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $13,665.24 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. This contract is for the delivery of KADCYLA 160 MG VIALS, a specialized pharmaceutical product. The contract has a performance period ending on July 27, 2022. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This IDC covers branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories. As a key supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group Inc. has demonstrated its capability to provide diverse pharmaceutical products to the DLA through multiple contract awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.7k | 7/6/22 |